JPRN-jRCT2080221411
Unknown
Phase 1
ONO-6950 Phase I Study (Single-dose, oral administration)
ConditionsAsthma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Enrollment
- 56
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Japanese healthy adult
- •2\. BMI of 18\.5\=\< \<25kg/m2
Exclusion Criteria
- •1\. Subject who has history or presence of clinically significant respiratory/pulmonary, cardiovascular, neurologic, psychiatric, digestive, hepatic, renal, hematopoietic, endocrine/metabolic diseases or disorders, and who is disqualified from the study at the discretion of primary investigator or sub\-investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 1
ONO-6950 Phase 1 StudyAsthmaJPRN-jRCT2080221601ONO PHARMACEUTICAL CO.,LTD.52
Completed
Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult SubjectsHealthy Adult SubjectsNCT01297582Ono Pharma USA Inc56
Unknown
Phase 1
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222143ONO PHARMACEUTICAL CO.,LTD.42
Terminated
Phase 1
Phase I dose-escalation study of oral administration of S055746 in patients with Acute Myeloid Leukaemia or Myelodysplastic SyndromeISRCTN73586707Institut de Recherches Internationales Servier (France)80
Not yet recruiting
Not Applicable
A Phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjectsDoor endotoxine veroorzaakte inflammatie reactieInflammationinnate immunesystem10002252NL-OMON36662Sirtris Pharmaceuticals, Inc.16